JP2022526504A5 - - Google Patents
Info
- Publication number
- JP2022526504A5 JP2022526504A5 JP2021556721A JP2021556721A JP2022526504A5 JP 2022526504 A5 JP2022526504 A5 JP 2022526504A5 JP 2021556721 A JP2021556721 A JP 2021556721A JP 2021556721 A JP2021556721 A JP 2021556721A JP 2022526504 A5 JP2022526504 A5 JP 2022526504A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- immune effector
- immunoeffector
- cells
- trail
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19164241.2 | 2019-03-21 | ||
| EP19164241.2A EP3712257A1 (en) | 2019-03-21 | 2019-03-21 | Modified natural killer cells with increased resistance to cell death |
| GBGB1917588.4A GB201917588D0 (en) | 2019-12-02 | 2019-12-02 | modified immune effector cells with increased resistance to cell death |
| GB1917588.4 | 2019-12-02 | ||
| GB2001593.9 | 2020-02-06 | ||
| GBGB2001593.9A GB202001593D0 (en) | 2020-02-06 | 2020-02-06 | Modified Immune effector cells with increased resistance to cell death |
| PCT/EP2020/057879 WO2020188105A1 (en) | 2019-03-21 | 2020-03-20 | Modified immune effector cells with increased resistance to cell death |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526504A JP2022526504A (ja) | 2022-05-25 |
| JP2022526504A5 true JP2022526504A5 (https=) | 2023-03-17 |
Family
ID=70165971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556721A Pending JP2022526504A (ja) | 2019-03-21 | 2020-03-20 | 細胞死に対する耐性が増大した改変免疫エフェクター細胞 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220143089A1 (https=) |
| EP (1) | EP3942022A1 (https=) |
| JP (1) | JP2022526504A (https=) |
| KR (1) | KR20210142665A (https=) |
| CN (1) | CN113677791B (https=) |
| AU (1) | AU2020242305A1 (https=) |
| BR (1) | BR112021018600B1 (https=) |
| CA (1) | CA3134223A1 (https=) |
| MX (1) | MX2021011373A (https=) |
| WO (1) | WO2020188105A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005277831B2 (en) | 2004-07-10 | 2012-11-22 | The Institute For Cancer Research | Genetically modified human natural killer cell lines |
| EP1621550A1 (en) * | 2004-07-29 | 2006-02-01 | Dompé S.P.A. | Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) |
| GB0724532D0 (en) * | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| JPWO2010101249A1 (ja) * | 2009-03-06 | 2012-09-10 | 国立大学法人三重大学 | Ｔ細胞の機能増強方法 |
| WO2015121454A1 (en) * | 2014-02-14 | 2015-08-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| EP4406604A3 (en) * | 2015-03-05 | 2024-10-23 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| JP6974681B2 (ja) * | 2015-07-29 | 2021-12-01 | オーエヌケー セラピューティクス リミテッド | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
| JP7086928B2 (ja) * | 2016-07-25 | 2022-06-20 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 改変されたナチュラルキラー細胞を生成する方法および使用方法 |
-
2020
- 2020-03-20 JP JP2021556721A patent/JP2022526504A/ja active Pending
- 2020-03-20 BR BR112021018600-0A patent/BR112021018600B1/pt not_active IP Right Cessation
- 2020-03-20 MX MX2021011373A patent/MX2021011373A/es unknown
- 2020-03-20 WO PCT/EP2020/057879 patent/WO2020188105A1/en not_active Ceased
- 2020-03-20 CN CN202080022826.1A patent/CN113677791B/zh not_active Expired - Fee Related
- 2020-03-20 AU AU2020242305A patent/AU2020242305A1/en not_active Abandoned
- 2020-03-20 US US17/441,674 patent/US20220143089A1/en not_active Abandoned
- 2020-03-20 CA CA3134223A patent/CA3134223A1/en active Pending
- 2020-03-20 EP EP20716707.3A patent/EP3942022A1/en not_active Withdrawn
- 2020-03-20 KR KR1020217032464A patent/KR20210142665A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gill et al. | Natural killer cells in allogeneic transplantation: effect on engraftment, graft-versus-tumor, and graft-versus-host responses | |
| Tang et al. | Immunotherapy in hematologic malignancies: achievements, challenges and future prospects | |
| Foley et al. | The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT) | |
| Song et al. | Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies | |
| JP2025013518A (ja) | Ｃａｒの抗腫瘍活性のための毒性管理 | |
| Leung | Infusions of allogeneic natural killer cells as cancer therapy | |
| Poccia et al. | CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes | |
| Sabry et al. | Tumor-primed NK cells: waiting for the green light | |
| JP2020509050A5 (https=) | ||
| JP2023530408A (ja) | Ｃｄ７０指向性がん免疫療法のための遺伝子修飾されたナチュラルキラー細胞 | |
| JP2021503954A5 (https=) | ||
| JP2021500881A5 (https=) | ||
| Dupont et al. | Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation | |
| JP2012254083A5 (https=) | ||
| JP2018524347A5 (https=) | ||
| Babor et al. | The role of KIR genes and ligands in leukemia surveillance | |
| Wang et al. | Can the dual-functional capability of CIK cells be used to improve antitumor effects? | |
| Wu et al. | Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers | |
| Stocker et al. | Pre-emptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes | |
| Peng et al. | A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy | |
| JP2022526504A5 (https=) | ||
| Hodges et al. | The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications | |
| Van Laecke et al. | Terminally differentiated effector memory T cells in kidney transplant recipients: New crossroads | |
| RU2021125300A (ru) | Модифицированные иммунные эффекторные клетки с повышенной устойчивостью к клеточной смерти | |
| Zhao et al. | Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress |